Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Accumulated Expenses (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Accumulated Expenses data on record, last reported at $245.1 million in Q2 2025.

  • For Q2 2025, Accumulated Expenses rose 1563.37% year-over-year to $245.1 million; the TTM value through Jun 2025 reached $245.1 million, up 1563.37%, while the annual FY2023 figure was $74.7 million, 153.66% up from the prior year.
  • Accumulated Expenses reached $245.1 million in Q2 2025 per RVMD's latest filing, up from $13.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $245.1 million in Q2 2025 and bottomed at $9.2 million in Q2 2023.
  • Average Accumulated Expenses over 5 years is $53.4 million, with a median of $29.4 million recorded in 2022.
  • The widest YoY moves for Accumulated Expenses: up 1563.37% in 2025, down 74.71% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $9.9 million in 2021, then soared by 198.88% to $29.4 million in 2022, then surged by 153.66% to $74.7 million in 2023, then grew by 4.44% to $78.0 million in 2024, then surged by 214.16% to $245.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $245.1 million in Q2 2025, $13.4 million in Q1 2025, and $78.0 million in Q3 2024.